Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 183 publications
Daratumumab in AL amyloidosis: survival, cardiac CR, and beyond.
Journal: Blood
Published: August 27, 2026
Ciltacabtagene autoleucel heralds the arrival of fixed-duration therapies in myeloma.
Journal: Nature reviews. Clinical oncology
Published: July 14, 2026
Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: June 11, 2026
Does ciltacabtagene autoleucel have a future in multiple myeloma?
Journal: Nature reviews. Clinical oncology
Published: June 08, 2026
Six Years Since Selinexor Approval for Relapsed Multiple Myeloma: What Have We Learned?
Journal: Cancer investigation
Published: June 05, 2026
Clinical trials portfolio and regulatory outcomes of ixazomib in multiple myeloma: A systematic review and meta-analysis.
Journal: British journal of haematology
Published: May 08, 2026
Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline Therapy.
Journal: American journal of hematology
Published: May 04, 2026
Use of CD38 Antibodies in High-Risk Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 16, 2026
A Clinically Applicable Conversion Formula between NT-proBNP and BNP in Light-Chain Amyloidosis.
Journal: JACC. CardioOncology
Published: March 16, 2026
The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population-Based Analysis.
Journal: American journal of hematology
Published: February 13, 2026
Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab-Treated Patients.
Journal: American journal of hematology
Published: January 20, 2026
Last Updated: 09/26/2026